Reimbursement for cancer treatment: Coverage of off-label drug indications from the American Society of Clinical Oncology, Alexandria, VA

Journal of Clinical Oncology

Volumn 24, Issue 19, 2006, Pages 3206-3208

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER THERAPY; CLINICAL PRACTICE; DRUG INFORMATION; HEALTH CARE ORGANIZATION; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; LAW; OFF LABEL DRUG USE; PRIORITY JOURNAL; REIMBURSEMENT; SHORT SURVEY; AGED; ARTICLE; DRUG LABELING; DRUG LEGISLATION; FOOD AND DRUG ADMINISTRATION; INSURANCE; LEGAL ASPECT; MEDICAID; MEDICARE; NEOPLASM; UNITED STATES;

AGED; ANTINEOPLASTIC AGENTS; DRUG LABELING; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH, REIMBURSEMENT; LEGISLATION, DRUG; MANAGED CARE PROGRAMS; MEDICAID; MEDICARE; NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34247362067     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.8940     Document Type: Short Survey

References (2)

1. National Cancer Institute: Understanding the Approval Process for New Cancer Treatments. http://newscenter.cancer.gov/clinicaltrials/learning/ approval-process-for-cancer-drugs/allpages/print
2. Statement of William B. Schultz, Deputy Commissioner for Policy, FDA, before the Committee on Labor and Human Resources, U.S. Senate, February 22, 1996. http://www.fda.gov/ola/1996/s1447.html